Metformin's Impact on the Microvascular Response to Insulin
Kaitlin M Love1, Eugene J Barrett1,2, William B Horton1
1Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Endocrinology
|October 6, 2022
Summary
Metformin enhances insulin
Area of Science:
- Endocrinology and Metabolism
- Vascular Biology
- Pharmacology
Background:
- Metformin is widely used to improve insulin sensitivity and glucose metabolism.
- Its effects on microvascular function and insulin action remain unclear.
- Understanding these mechanisms is crucial for optimizing treatment.
Purpose of the Study:
- To review the current understanding of metformin's impact on microvascular function and insulin response.
- To identify methodological challenges in studying these effects.
- To propose potential mechanisms and future research directions.
Main Methods:
- Mini-review of existing literature.
- Analysis of pharmacologically dosed studies.
- Examination of potential mechanisms including oxidative stress, inflammation, and endothelial dysfunction.
Main Results:
- Metformin shows beneficial effects on microvascular function and insulin response.
- Methodological limitations hinder a clear mechanistic understanding.
- Potential mechanisms involve reducing oxidative stress, inflammation, and endothelial dysfunction.
Conclusions:
- Metformin may improve microvascular insulin resistance through anti-inflammatory and antioxidant pathways.
- Further research is needed to link microvascular improvements to vascular outcomes.
- Clarifying these mechanisms could enhance metformin's therapeutic applications.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
269
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
269
Dipeptidyl Peptidase 4 Inhibitors
235
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
235
Oral Hypoglycemic Agents: Glinides
226
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
226
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
238
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
238
Insulin: Dosing Regimen and Adverse Effects
229
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
229
Hormones Regulating Blood Glucose
3.7K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.7K


